Cardiac cell loss marks the transition from hypertrophy to heart failure and is the likely result of chronic myocardial ischemia and cell hypoxia. Cell loss is due predominantly to the death of cardiac myocytes and is mediated in part by apoptosis. Because adult cardiac myocytes are terminally differentiated cells, the effects of such loss can never be full compensated. The identification of the intracellular signaling events and extracellular factors that regulate this process and the development of strategies to prevent such loss is, therefore, likely to have important beneficial consequences. We have adopted an experimental system to induce cardiomyocyte cell death by apoptosis that involves exposing neonatal cardiomyocytes to prolonged hypoxia. We show that in these cells there is increased expression and transactivating ability by the tumor suppressor gene, p53, that accompanies the onset of apoptotic cell death. In addition, expression of p21/WAF1, a downstream target of p53, also increases during hypoxia. Forced expression of either p53 or p21/WAF1 in normoxic myocytes through infection with recombinant adenoviruses leads to apoptosis, as does the incubation of normoxic myocytes with bafilomycin, an inhibitor of membrane-associated proton pumps which, in other cell types, leads to intracellular acidification. Apoptosis induced by all these different mechanisms (hypoxia, infection with recombinant adenoviruses expressing p53 and p21, and bafilomycin) is effectively prevented by exposure to the hypertrophy-inducing factor, phenylephrine. The demonstration that p53 is involved in the apoptosis of cardiac myocytes was unexpected since these cells are terminally growth arrested. Because the p53 pathway for apoptosis is often associated with cellular stress and p53 knockout mice show no overt cardiac defects, a strategy to prevent apoptosis that involves inactivating p53 is unlikely to interfere with the normal tissue remodelling necessary for heart formation.
| Neuss, M; Crow, M T; Chesley, A et al. (2001) Apoptosis in cardiac disease--what is it--how does it occur. Cardiovasc Drugs Ther 15:507-23 |
| Senzaki, H; Paolocci, N; Gluzband, Y A et al. (2000) beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res 86:807-15 |
| Chesley, A; Lundberg, M S; Asai, T et al. (2000) The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. Circ Res 87:1172-9 |
